JP7103751B6 - 修飾された抗原結合ポリペプチド構築物及びその使用 - Google Patents

修飾された抗原結合ポリペプチド構築物及びその使用 Download PDF

Info

Publication number
JP7103751B6
JP7103751B6 JP2016569603A JP2016569603A JP7103751B6 JP 7103751 B6 JP7103751 B6 JP 7103751B6 JP 2016569603 A JP2016569603 A JP 2016569603A JP 2016569603 A JP2016569603 A JP 2016569603A JP 7103751 B6 JP7103751 B6 JP 7103751B6
Authority
JP
Japan
Prior art keywords
amino acid
acid substitutions
heterodimer
antigen
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016569603A
Other languages
English (en)
Japanese (ja)
Other versions
JP7103751B2 (ja
JP2018502550A5 (https=
JP2018502550A (ja
Inventor
マリオ サンチェス
フォン クレウデンステイン トーマス スプレター
ドウニャ ウロセブ
ステイシー エー．エル． トム‐ユー
アダム ルイ コーパー
イゴール エドモンド パオロ ダンジェロ
ヤン‐チエ チョウ
スージット ビームラーオ ディクシット
Original Assignee
ザイムワークス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイムワークス，インコーポレイテッド filed Critical ザイムワークス，インコーポレイテッド
Priority claimed from PCT/IB2015/054107 external-priority patent/WO2015181805A1/en
Publication of JP2018502550A publication Critical patent/JP2018502550A/ja
Publication of JP2018502550A5 publication Critical patent/JP2018502550A5/ja
Publication of JP7103751B2 publication Critical patent/JP7103751B2/ja
Application granted granted Critical
Publication of JP7103751B6 publication Critical patent/JP7103751B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016569603A 2015-04-28 2015-05-29 修飾された抗原結合ポリペプチド構築物及びその使用 Active JP7103751B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154055P 2015-04-28 2015-04-28
US62/154,055 2015-04-28
PCT/IB2015/054107 WO2015181805A1 (en) 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020137041A Division JP7183221B2 (ja) 2015-04-28 2020-08-14 修飾された抗原結合ポリペプチド構築物及びその使用

Publications (4)

Publication Number Publication Date
JP2018502550A JP2018502550A (ja) 2018-02-01
JP2018502550A5 JP2018502550A5 (https=) 2018-07-05
JP7103751B2 JP7103751B2 (ja) 2022-07-20
JP7103751B6 true JP7103751B6 (ja) 2022-08-15

Family

ID=58848603

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569603A Active JP7103751B6 (ja) 2015-04-28 2015-05-29 修飾された抗原結合ポリペプチド構築物及びその使用
JP2020137041A Active JP7183221B2 (ja) 2015-04-28 2020-08-14 修飾された抗原結合ポリペプチド構築物及びその使用
JP2022186638A Pending JP2023027107A (ja) 2015-04-28 2022-11-22 修飾された抗原結合ポリペプチド構築物及びその使用
JP2024104675A Pending JP2024125389A (ja) 2015-04-28 2024-06-28 修飾された抗原結合ポリペプチド構築物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020137041A Active JP7183221B2 (ja) 2015-04-28 2020-08-14 修飾された抗原結合ポリペプチド構築物及びその使用
JP2022186638A Pending JP2023027107A (ja) 2015-04-28 2022-11-22 修飾された抗原結合ポリペプチド構築物及びその使用
JP2024104675A Pending JP2024125389A (ja) 2015-04-28 2024-06-28 修飾された抗原結合ポリペプチド構築物及びその使用

Country Status (3)

Country Link
JP (4) JP7103751B6 (https=)
KR (2) KR102669686B1 (https=)
CN (1) CN106661121A (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP7654539B2 (ja) * 2018-09-07 2025-04-01 ファイザー・インク 抗αｖβ８抗体、組成物及びその使用
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
JP7535273B2 (ja) * 2019-04-26 2024-08-16 スアンズ バイオファーマシューティカル カンパニー，リミテッド Ｃｄ８０バリアントタンパク質とその使用
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
CA3217487A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
JP2024544607A (ja) * 2021-11-25 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー 少量の抗体副産物の定量
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082179A1 (en) 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
CN107501407B (zh) * 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
DK2786762T3 (da) * 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR112013023918A2 (pt) * 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
SG11201401422VA (en) * 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
IN2015DN01299A (https=) * 2012-07-23 2015-07-03 Zymeworks Inc
CA3244731A1 (en) * 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082179A1 (en) 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Also Published As

Publication number Publication date
JP7103751B2 (ja) 2022-07-20
KR20230019503A (ko) 2023-02-08
JP7183221B2 (ja) 2022-12-05
JP2020202848A (ja) 2020-12-24
JP2024125389A (ja) 2024-09-18
CN106661121A (zh) 2017-05-10
KR20240093883A (ko) 2024-06-24
KR102669686B1 (ko) 2024-05-29
JP2023027107A (ja) 2023-03-01
JP2018502550A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
US12286489B2 (en) Modified antigen binding polypeptide constructs and uses thereof
JP7080955B2 (ja) 遺伝子操作された免疫グロブリン重鎖－軽鎖対およびその使用
JP7183221B2 (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
RU2826203C1 (ru) Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение
HK40077442A (en) Modified antigen binding polypeptide constructs and uses thereof
HK1237351A1 (en) Modified antigen binding polypeptide constructs and uses thereof
BR112015012385B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, uso do constructo, métodos para obter o constructo, método para preparar o constructo e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico
BR122021004365B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, métodos para obter o constructo e uso do constructo
HK40121604A (zh) 工程化免疫球蛋白重链-轻链对及其用途
HK40121605A (zh) 工程化免疫球蛋白重链-轻链对及其用途
BR122021004364B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, métodos para obter o constructo e uso do constructo
HK1216899B (zh) 工程化免疫球蛋白重链-轻链对及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180119

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200814

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200824

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200825

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200911

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200915

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210511

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210720

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211012

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20211102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220329

C30 Protocol of an oral hearing

Free format text: JAPANESE INTERMEDIATE CODE: C30

Effective date: 20220414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20220510

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220517

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220614

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220707

R150 Certificate of patent or registration of utility model

Ref document number: 7103751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250